{"id":"NCT04268771","sponsor":"Dr. Reddy's Laboratories Limited","briefTitle":"A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products","officialTitle":"A Randomized, Double-blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan速 or MabThera速","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-04-08","primaryCompletion":"2022-01-26","completion":"2022-04-20","firstPosted":"2020-02-13","resultsPosted":"2023-11-18","lastUpdate":"2023-11-18"},"enrollment":140,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Experimental: Arm A: DRL_RI","otherNames":[]},{"type":"BIOLOGICAL","name":"Arm B: Rituxan速/Mabthera速","otherNames":[]}],"arms":[{"label":"Arm A: DRL_RI","type":"EXPERIMENTAL"},{"label":"Arm B: US-Rituximab or EU-Rituximab","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of the current study is to assess the immunogenicity and safety of transitioning subjects with RA to DRL\\_RI from US-rituximab/EU-rituximab to continued treatment with US-rituximab/EU-rituximab.\n\nThe primary objective of this study is to assess the immunogenicity of transitioning subjects with RA to DRL\\_RI (biosimilar rituximab) from US-rituximab/EU-rituximab to continued treatment with US-rituximab/EU-rituximab\n\nTo assess the safety of transitioning subjects with RA to DRL\\_RI from US-rituximab/EU-rituximab to continued treatment with US-rituximab/EU-rituximab.","primaryOutcome":{"measure":"Number of Subjects With Positive Anti-Drug Antibodies (ADA) on Day 1","timeFrame":"ADA will be obtained before the administration of study treatment on Day 1","effectByArm":[{"arm":"Arm A: DRL_RI","deltaMin":3,"sd":null},{"arm":"Arm B: US-Rituximab or EU-Rituximab","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":26,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":70},"commonTop":["Diarrhoea","Headache","COVID-19","Nasopharyngitis"]}}